Skip to content
Study details
Enrolling now

Ondansetron for Atrial Fibrillation

Indiana University
NCT IDNCT05844501ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

80

Study length

about 2.7 years

Ages

18–100

Locations

3 sites in IN

What this study is about

Researchers are testing whether ondansetron, a medication used to prevent nausea, can help manage atrial fibrillation (Afib). The trial will involve 80 adults scheduled for an Afib ablation procedure. Participants will be randomly assigned to receive either ondansetron or a placebo for 28 days before the procedure and will have their time in Afib and heart rate monitored.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Ondansetron 8mg
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ondansetron (5-HT3 receptor antagonist; prevents nausea/vomiting)

Drug routes

injection

Endpoints

Secondary: Adverse effects

Body systems

Cardiology / Heart